Finisar Corporation (FNSR) Jumps 6.72% on February 03

Equities Staff |

Finisar Corporation (FNSR) was among the biggest gainers on the Russell 2000 for Wednesday February 03 as the stock popped 6.72% to $13.19, representing a gain of $0.83 per share. Some 1.1 million shares traded hands on 6,995 trades, compared with an average daily volume of 1.25 million shares out of a total float of 106.96 million. The stock opened at $12.55 and traded with an intraday range of $13.25 to $12.51.

After today's gains, Finisar Corporation reached a market cap of $1.41 billion. Finisar Corporation has had a trading range between $23.38 and $10.66 over the last year, and it had a 50-day SMA of $13.06 and a 200-day SMA of $15.73.

The stock has a P/E Ratio of 68.4.

Finisar Corp is a provider of optical subsystems and components that are used in data communication and telecommunication applications.

Finisar Corporation is based out of Sunnyvale, CA and has some 13,400 employees. Its CEO is Jerry S. Rawls.

For a complete fundamental analysis analysis of Finisar Corporation, check out’s Stock Valuation Analysis report for FNSR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…